195 related articles for article (PubMed ID: 11590509)
1. Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals.
Touloumi G; Paparizos V; Sambatakou H; Katsarou O; Chrysos G; Kordossis T; Antoniadou A; Hatzitheodorou H; Stavrianeas N; Gargalianos P; Karafoulidou A; Lazanas M; Giamarelou H; Hatzakis A
HIV Clin Trials; 2001; 2(1):6-16. PubMed ID: 11590509
[TBL] [Abstract][Full Text] [Related]
2. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
Bisson GP; Gross R; Strom JB; Rollins C; Bellamy S; Weinstein R; Friedman H; Dickinson D; Frank I; Strom BL; Gaolathe T; Ndwapi N
AIDS; 2006 Aug; 20(12):1613-9. PubMed ID: 16868442
[TBL] [Abstract][Full Text] [Related]
4. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
Wu H; Connick E; Kuritzkes DR; Landay A; Spritzler J; Zhang B; Spear GT; Kessler H; Lederman MM;
AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1231-40. PubMed ID: 11559422
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
7. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
[TBL] [Abstract][Full Text] [Related]
9. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
[TBL] [Abstract][Full Text] [Related]
10. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
[TBL] [Abstract][Full Text] [Related]
11. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort.
Rudy BJ; Lindsey JC; Flynn PM; Bosch RJ; Wilson CM; Hughes ME; Douglas SD;
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):213-21. PubMed ID: 16545007
[TBL] [Abstract][Full Text] [Related]
12. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
[TBL] [Abstract][Full Text] [Related]
13. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A
AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661
[TBL] [Abstract][Full Text] [Related]
14. Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch.
Tomasoni LR; Patroni A; Torti C; Paraninfo G; Gargiulo F; Quiros-Roldan E; Uccelli MC; Airò P; Tinelli C; Carosi G; Castelli F;
HIV Clin Trials; 2003; 4(5):311-23. PubMed ID: 14583847
[TBL] [Abstract][Full Text] [Related]
15. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Deeks SG; Barbour JD; Grant RM; Martin JN
AIDS; 2002 Jan; 16(2):201-7. PubMed ID: 11807304
[TBL] [Abstract][Full Text] [Related]
16. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection.
Kaufmann GR; Khanna N; Weber R; Perrin L; Furrer H; Cavassini M; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Antivir Ther; 2004 Apr; 9(2):263-74. PubMed ID: 15134189
[TBL] [Abstract][Full Text] [Related]
17. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.
Salzberger B; Rockstroh J; Wieland U; Franzen C; Schwenk A; Jütte A; Hegener P; Cornely O; Mörchen C; Gaensicke T; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Nov; 4(11):449-55. PubMed ID: 10585299
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART.
Nicastri E; Chiesi A; Angeletti C; Sarmati L; Palmisano L; Geraci A; Andreoni M; Vella S;
J Med Virol; 2005 Jun; 76(2):153-60. PubMed ID: 15834865
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.
Vaamonde CM; Hoover DR; Anastos K; Tan T; Shi Q; Gao W; Kovacs A; Cohen M; DeHovitz J; Glesby MJ
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):222-31. PubMed ID: 16545008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
